UroGen: Expect Rough Patch Before Strong Recovery In 2026

UroGen Pharma (URGN) has seen its stock appreciate by approximately 95% since a previous 'Strong Buy' rating, driven by its RTGel technology products JELMYTO and ZUSDURI. While JELMYTO's revenue growth is now tapering, the recently approved ZUSDURI is projected to experience significant revenue acceleration and achieve blockbuster status starting in January 2026, coinciding with the activation of its independent J-Code, indicating a potential near-term revenue lull before a strong recovery.

Analysis

UroGen Pharma (URGN) has demonstrated substantial market performance, with its stock appreciating approximately 95% since a previous 'Strong Buy' rating, underpinned by its proprietary RTGel technology. While the company's existing product, JELMYTO, is experiencing a tapering of its revenue growth, indicating a maturing phase for this asset.

The recently FDA-approved ZUSDURI, greenlit in June 2025, is positioned as the next significant growth catalyst. However, its revenue contribution is expected to remain subdued until January 2026, coinciding with the activation of its independent J-Code, which is crucial for reimbursement and broader market access.

Post-January 2026, ZUSDURI is projected to achieve strong revenue acceleration and eventually reach blockbuster status, signaling a potential near-term revenue lull for URGN followed by a robust recovery and growth trajectory. This outlook aligns with the strongly positive sentiment and bullish tone observed in recent analyst assessments.

Key Decisions for Investors

• Investors should closely monitor UroGen Pharma's revenue performance for the anticipated lull in late 2025, as JELMYTO's growth tapers and ZUSDURI awaits its J-Code activation.
• Assess the successful market penetration and revenue ramp-up of ZUSDURI post-January 2026 as a critical indicator for the company's projected blockbuster status and long-term growth.
• Consider the analyst's disclosed long position and the overall bullish sentiment surrounding URGN, but also factor in the inherent risks associated with product launch timelines and market adoption rates.